These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 9573914)

  • 21. 5-Hydroxytryptamine (serotonin) subtype 3 antagonists, a major step in prophylaxis and control of cytostatic and radiation-induced emesis.
    Bremer K
    J Cancer Res Clin Oncol; 1991; 117(1):85-7. PubMed ID: 1997476
    [No Abstract]   [Full Text] [Related]  

  • 22. Tropisetron (Navoban): just another "setron"?
    Aapro MS
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):1-2. PubMed ID: 9113118
    [No Abstract]   [Full Text] [Related]  

  • 23. [Gastrointestinal complication of cancer chemotherapy].
    Hamaguchi T
    Nihon Rinsho; 2007 Oct; 65 Suppl 8():281-6. PubMed ID: 18074549
    [No Abstract]   [Full Text] [Related]  

  • 24. Chemotherapy-induced nausea and vomiting.
    Hesketh PJ
    N Engl J Med; 2008 Jun; 358(23):2482-94. PubMed ID: 18525044
    [No Abstract]   [Full Text] [Related]  

  • 25. Chemotherapy-induced emesis in elderly cancer patients: the role of 5-HT3-receptor antagonists in the first 24 hours.
    Aapro M; Johnson J
    Gerontology; 2005; 51(5):287-96. PubMed ID: 16110229
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ondansetron: a specific serotonin antagonist for the prevention of chemotherapy-induced vomiting.
    Kris MG
    Important Adv Oncol; 1994; ():165-77. PubMed ID: 8206488
    [No Abstract]   [Full Text] [Related]  

  • 27. Itasetron. DAU 6215, U 98079.
    Drugs R D; 1999 Oct; 2(4):243-4. PubMed ID: 10659399
    [No Abstract]   [Full Text] [Related]  

  • 28. New agents for controlling emesis with cancer chemotherapy.
    Gralla RJ; Clark RA
    J La State Med Soc; 1993 Apr; 145(4):169-73. PubMed ID: 8486990
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evolving paradigms in chemotherapy-induced nausea and vomiting and symptom management for the breast cancer patient.
    Biedrzycki BA
    ONS Connect; 2007; 22(8 Suppl):9-10. PubMed ID: 17824543
    [No Abstract]   [Full Text] [Related]  

  • 30. New treatment options for chemotherapy-induced nausea and vomiting.
    Hesketh PJ
    Support Care Cancer; 2004 Aug; 12(8):550-4. PubMed ID: 15232725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiemetic treatment for cancer chemotherapy: problems and progress.
    Gralla RJ
    Support Care Cancer; 1994 Sep; 2(5):275-6. PubMed ID: 8000721
    [No Abstract]   [Full Text] [Related]  

  • 32. Update on the management of chemotherapy-related nausea and vomiting: an emphasis on the new class of agents--neurokinin-1 receptor antagonists.
    Gralla R
    Clin Adv Hematol Oncol; 2006 Jul; 4(7):507-8. PubMed ID: 17147235
    [No Abstract]   [Full Text] [Related]  

  • 33. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy.
    Gregory RE; Ettinger DS
    Drugs; 1998 Feb; 55(2):173-89. PubMed ID: 9506240
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients?
    de Wit R; Aapro M; Blower PR
    Cancer Chemother Pharmacol; 2005 Sep; 56(3):231-8. PubMed ID: 15838653
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serotonin antagonists: treatment of chemotherapy-induced emesis.
    Barisano A; Mehl B; Bradbury K
    Mt Sinai J Med; 1992 Oct; 59(5):433-7. PubMed ID: 1435844
    [No Abstract]   [Full Text] [Related]  

  • 36. Oral serotonin type 3-receptor antagonists for prevention of chemotherapy-induced emesis.
    Lindley C; Blower P
    Am J Health Syst Pharm; 2000 Sep; 57(18):1685-97. PubMed ID: 11006796
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiemetic control: 5-HT3 antagonists: review of clinical results, with particular emphasis on ondansetron.
    Kidgell AE; Butcher ME; Brown GW
    Cancer Treat Rev; 1990 Sep; 17(2-3):311-7. PubMed ID: 2176933
    [No Abstract]   [Full Text] [Related]  

  • 38. Nausea and vomiting associated with cancer chemotherapy: drug management in theory and in practice.
    Antonarakis ES; Hain RD
    Arch Dis Child; 2004 Sep; 89(9):877-80. PubMed ID: 15321871
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progress in controlling emesis with cancer chemotherapy.
    Gralla RJ; Clark RA
    Support Care Cancer; 1993 Jul; 1(4):178-81. PubMed ID: 8193878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overview: oral granisetron (Kytril tablets) prophylaxis for chemotherapy-induced nausea and vomiting.
    Perez EA
    Semin Oncol; 1995 Aug; 22(4 Suppl 10):1-2. PubMed ID: 7570049
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.